WTA World No. 2 Iga Swiatek changed her public relations representation after almost four years amid her doping controversy.

Swiatek said she couldn't play over the fall owing to 'personal matters'. That didn't really explain what was going on

Iga Swiatek is the second high-profile tennis player to test positive for a banned substance this year, joining Jannik Sinner. While Sinner, currently the No. 1 ranked man, was fully cleared, Swiatek, who slid from No. 1 to No. 2 last month, accepted a one-month suspension that was announced Thursday.

The results for unspecified substances resulted in a mandatory provisional suspension, imposed on September 12th. This resulted in the Pole having to miss the WTA 500 in Korea (September 16-22), the WTA 1000 in Beijing (September 25-October 6) and the WTA 1000 in Wuhan (October 7-13).

The five-time Grand Slam champion has served 22 days of a one-month ban from tennis. Here's what you need to know

The International Tennis Integrity Agency says five-time Grand Slam champion Iga Swiatek has accepted a one-month suspension after testing positive for the banned substance trimetazidine.

The women's tennis association stands by the Polish player, after the doping issue and the one-month suspension

Iga Swiatek received a one-month ban after positive drug test and will be eligible to play in the Australian Open.

Swiatek said a batch of melatonin she used was contaminated with a banned substance, an explanation anti-doping authorities said they accepted after a probe.

Meanwhile, Swiatek was found to have been “at the lowest end of the range for no significant fault or negligence” after the 23-year-old Polish player explained that her doping violation was caused by a contaminated supply of the non-prescription medication melatonin, which she uses to help with jet lag and sleep issues.

World number two Iga Swiatek has accepted a one-month suspension after testing positive for the prohibited substance trimetazidine (TMZ).